Tesamorelin and visceral fat

Plain-language summary

Tesamorelin is unusual in this space: it's an actually-approved drug, with real randomized trials behind it. It stimulates your own growth hormone via the GHRH receptor and has been shown to reduce deep abdominal (visceral) fat. The important asterisk is who it was studied in—people with HIV-associated fat redistribution—which is not the same as a healthy person wanting a leaner midsection.

What was studied

Randomized controlled trials measuring visceral adipose tissue (and, in some work, liver fat) in adults with HIV-associated lipodystrophy, along with IGF-1 and glucose-related markers.

Key takeaways

• Trials support genuine visceral-fat reduction in the labeled population—this is a stronger-clinical evidence tier.
• It works by raising your own GH secretion, not by injecting GH directly.
• Effects on IGF-1 and glucose are part of the picture and are monitored clinically.
• It's a prescription product with a specific indication, not a general “fat-loss peptide.”

Limitations & what we don't know

• The strong data are in HIV-associated lipodystrophy; extrapolation to general aesthetic fat loss is not supported by these trials.
• IGF-1 elevation and glucose effects warrant clinical monitoring.
• Injection-site reactions are documented.
• Off-label athletic use lacks strong outcome data.

1. 1.

   Effects of tesamorelin on visceral fat and liver fat in HIV

   2014 · human

   Visceral and hepatic fat changes examined.

2. 2.

   Tesamorelin for reduction of visceral fat in HIV-associated lipodystrophy

   2010 · human

   Pivotal evidence for VAT reduction.